CN1723285B - 重组的mva及其产生方法 - Google Patents

重组的mva及其产生方法 Download PDF

Info

Publication number
CN1723285B
CN1723285B CN2004800018495A CN200480001849A CN1723285B CN 1723285 B CN1723285 B CN 1723285B CN 2004800018495 A CN2004800018495 A CN 2004800018495A CN 200480001849 A CN200480001849 A CN 200480001849A CN 1723285 B CN1723285 B CN 1723285B
Authority
CN
China
Prior art keywords
mva
dna
gene
sequence
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800018495A
Other languages
English (en)
Chinese (zh)
Other versions
CN1723285A (zh
Inventor
卡罗琳·斯泰伯
玛丽亚纳·洛维尔
沃克·爱尔福勒
歌德·萨特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of CN1723285A publication Critical patent/CN1723285A/zh
Application granted granted Critical
Publication of CN1723285B publication Critical patent/CN1723285B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2004800018495A 2003-02-18 2004-02-18 重组的mva及其产生方法 Expired - Fee Related CN1723285B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44823103P 2003-02-18 2003-02-18
US60/448,231 2003-02-18
PCT/EP2004/001554 WO2004074493A1 (en) 2003-02-18 2004-02-18 Recombinant mva and method for generation thereof

Publications (2)

Publication Number Publication Date
CN1723285A CN1723285A (zh) 2006-01-18
CN1723285B true CN1723285B (zh) 2013-01-02

Family

ID=32908561

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800018495A Expired - Fee Related CN1723285B (zh) 2003-02-18 2004-02-18 重组的mva及其产生方法

Country Status (8)

Country Link
US (1) US20060002896A1 (enExample)
EP (1) EP1594970B1 (enExample)
JP (2) JP4686443B2 (enExample)
CN (1) CN1723285B (enExample)
AT (1) ATE403005T1 (enExample)
DE (1) DE602004015418D1 (enExample)
DK (1) DK1594970T3 (enExample)
WO (1) WO2004074493A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
AU2003297499A1 (en) 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
CN102559611B (zh) * 2011-06-23 2015-04-22 江苏省农业科学院 一种无筛选标记的双表达重组mva病毒及其构建方法
US10736962B2 (en) * 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
NZ750578A (en) * 2016-08-19 2023-05-26 Sementis Ltd Viral vaccines
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1189857A (zh) * 1995-07-04 1998-08-05 Gsf环境与健康研究中心有限公司 重组mva病毒及其应用
WO2002090550A2 (en) * 2001-05-10 2002-11-14 Isis Innovation Limited Method for preparing recombinant poxvirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
BR0111366A (pt) * 2000-05-24 2003-05-20 Merial Sas Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1189857A (zh) * 1995-07-04 1998-08-05 Gsf环境与健康研究中心有限公司 重组mva病毒及其应用
WO2002090550A2 (en) * 2001-05-10 2002-11-14 Isis Innovation Limited Method for preparing recombinant poxvirus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C. Staib et al.,.Transient host range selection for genetic engineeringof modified vaccinia virus Ankara.BioTechniques28 6.2000,28(6),1138页第3栏第13行，1139页第2栏第1行至1141页左栏第36行，1141页右栏最后4行以及1144页第1栏第1-23行，1144页第2栏倒数第4行至1145页右栏第27行,1146页第3栏第13-16行，图2和3.
C. Staib et al.,.Transient host range selection for genetic engineeringof modified vaccinia virus Ankara.BioTechniques28 6.2000,28(6),1138页第3栏第13行,1139页第2栏第1行至1141页左栏第36行,1141页右栏最后4行以及1144页第1栏第1-23行,1144页第2栏倒数第4行至1145页右栏第27行,1146页第3栏第13-16行,图2和3. *
C. Staib et al.,.Transient host range selection for genetic engineeringofmodified vaccinia virus Ankara.BioTechniques28 6.2000,1138页第3栏第13行，1139页第2栏第1行至1141页左栏第36行，1141页右栏最后4行以及1144页第1栏第1-23行，1144页第2栏倒数第4行至1145页右栏第27行,1146页第3栏第13-16行，图2和3.
C. Staib et al.,.Transient host range selection for genetic engineeringofmodified vaccinia virus Ankara.BioTechniques28 6.2000,1138页第3栏第13行,1139页第2栏第1行至1141页左栏第36行,1141页右栏最后4行以及1144页第1栏第1-23行,1144页第2栏倒数第4行至1145页右栏第27行,1146页第3栏第13-16行,图2和3. *
H. Meyer et al.,.Mapping of deletions in the genome of the highly attenuatedvaccinia virus MVA and their influence on virulence.Journal of General Virology 72.1991,1031-1038.
H. Meyer et al.,.Mapping of deletions in the genome of the highly attenuatedvaccinia virus MVA and their influence on virulence.Journal of General Virology 72.1991,1031-1038. *

Also Published As

Publication number Publication date
JP5166505B2 (ja) 2013-03-21
DK1594970T3 (da) 2008-11-17
JP4686443B2 (ja) 2011-05-25
JP2006517795A (ja) 2006-08-03
US20060002896A1 (en) 2006-01-05
EP1594970A1 (en) 2005-11-16
CN1723285A (zh) 2006-01-18
WO2004074493A1 (en) 2004-09-02
DE602004015418D1 (de) 2008-09-11
JP2011055840A (ja) 2011-03-24
EP1594970B1 (en) 2008-07-30
ATE403005T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
AU619235B2 (en) Recombinant vaccinia virus mva
US7198934B2 (en) Recombinant MVA virus, and the use thereof
JP5166505B2 (ja) 組換えｍｖａおよびその生産方法
CN1653183B (zh) 表达插入痘病毒基因组中的同源基因的重组痘病毒
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
EP1425404B1 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
CN106318978A (zh) 包含多个同源核苷酸序列的载体
JP2013014588A (ja) Ｍｖａの使用に基づくワクチン
CN104812894B (zh) 新型mva病毒及其用途
MXPA04011034A (es) Expresion de los genes en el virus de la vacuna de ankara modificada, usando el promotor ati de viruela.
JP2005525119A (ja) 組換え鶏痘ウイルス
JP2005534326A (ja) アビポックスウイルスの力価を増加させるためのワクシニアウイルス宿主域遺伝子
US11104884B2 (en) Vaccinia virus vectors related to MVA with extensive genomic symmetries
JP7034818B2 (ja) 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法
HK1076835B (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
HK1068015B (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: HEALTH AND ENVIRONMENT CO., LTD. OF HELMHOLTZ RESE

Free format text: FORMER OWNER: GSF FORSCHUNGSZENTRUM UMWELT

Effective date: 20100706

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100706

Address after: Munich, Germany

Applicant after: Helmholtz Zentrum Muenchen

Address before: Munich, Germany

Applicant before: Gsf Forschungszentrum Umwelt

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130102

Termination date: 20140218